Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $19.00

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned an average rating of “Hold” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $19.00.

FULC has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Citigroup reaffirmed an “underperform” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. HC Wainwright lifted their target price on Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th.

Fulcrum Therapeutics Stock Performance

FULC stock opened at $11.58 on Thursday. The stock has a market cap of $626.69 million, a P/E ratio of -9.81 and a beta of 3.17. The firm has a 50 day simple moving average of $10.39 and a 200 day simple moving average of $8.48. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Sell-side analysts predict that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Insider Buying and Selling

In other news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total transaction of $165,450.00. Following the sale, the director directly owned 484,864 shares of the company’s stock, valued at $5,348,049.92. This represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the sale, the insider owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FULC. Vanguard Personalized Indexing Management LLC lifted its stake in Fulcrum Therapeutics by 26.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after buying an additional 2,677 shares in the last quarter. Strs Ohio raised its holdings in shares of Fulcrum Therapeutics by 3.7% during the third quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after acquiring an additional 2,800 shares during the period. American Century Companies Inc. lifted its position in Fulcrum Therapeutics by 2.6% in the 1st quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock valued at $356,000 after acquiring an additional 3,100 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares during the period. Finally, Quarry LP bought a new position in Fulcrum Therapeutics during the 3rd quarter worth about $35,000. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.